Syntiron today announced that it has granted sanofi pasteur an exclusive
world-wide license to its human vaccine against Staphylococcus aureus.
The agreement includes an undisclosed initial licensing fee, milestone
payments and royalty payments on future sales of the product. Staphylococcus
aureus, or MRSA (pronounced Mer-sa) is an important
hospital-acquired infection and is a major cause of illness and death
resulting in excess of 18,000 US deaths a year and a half million
hospitalizations, creating a significant economic burden of
approximately $3.4 billion annually to the American health care system.
Syntiron is a private biotech company located in St. Paul, Minnesota;
its mission is the prevention and treatment of human disease resulting
from bacterial infection. Under the terms of the agreement, sanofi
pasteur will support the joint, pre-clinical development of the product,
working cooperatively with Syntiron, and be responsible for all future
developments, regulatory approval, and commercialization of the vaccine.
Neither company spelled out the terms, but Syntiron gets an upfront
payment, research funding and is eligible for development, regulatory
and commercial milestone payments that could reach $149 million in
total. Syntiron also stands to earn royalties on sales of products
commercialized under the license and collaboration.